Nigerian Para Powerlifter Banned For 30 Months

Nigerian Para Powerlifter Banned For 30 Months 2
File photograph of former Paralympic champion, Paul Kehinde

 

The International Paralympic Committee (IPC) has banned former Paralympic champion Para powerlifter, Paul Kehinde for 30 months for an anti-doping rule violation (ADRV).

Kehinde, who received gold on the Rio 2016 Paralympic Games within the Men’s as much as 65kg, returned an opposed analytical discovering (AAF) for prohibited substances in a urine pattern supplied out-of-competition on March 9, 2020.

The substances had been hydrochlorothiazide and its metabolite and amiloride and had been included on the World Anti-Doping Agency (WADA) 2020 Prohibited List below the category S5 Diuretics and Masking Agents. This is the athlete’s second ADRV.

As a results of his violation, the Nigerian shall be ineligible for competitors for 30 months from March 9, 2020 to September 8, 2022. The outcomes obtained by the athlete from the date the pattern was collected will even be disqualified, with all ensuing penalties, together with forfeiture of any medals, factors and prizes.

James Sclater, Anti-Doping Director on the IPC, stated: “This case could have been averted if the athlete had adopted the principles for Therapeutic Use Exemptions (TUEs) and verified that his prescribed remedy was prohibited.

“The IPC would like to strongly remind all athletes who require the use of a prohibited substance or method, for a diagnosed medical condition, to apply for a TUE in accordance with the WADA ISTUE requirements.”

Each athlete is strictly accountable for the substances present in his or her pattern. An ADRV happens at any time when a prohibited substance (or its metabolites or markers) is present in his or her bodily specimen, whether or not or not the athlete deliberately or unintentionally used a prohibited substance or was negligent or in any other case at fault.

Leave a Reply

Your email address will not be published.

Nigerian Para Powerlifter Banned For 30 Months

Send this to a friend